Liver-based in vitro technologies for drug biotransformation studies - A review

Current Drug Metabolism

Volumn 13, Issue 2, 2012, Pages 215-224

  Fasinu, Pius ^a   Bouic, Patrick J ^a,b   Rosenkranz, Bernd ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b Stellenbosch University Synexa Life Sciences   (South Africa)

Author keywords

Biotransformation; Cytochrome P450; In vitro metabolism; Liver cytosol; Liver slices; Microsomes; S9 fractions; Subcellular fractions; UDT glucuronosyltransferase

Indexed keywords

CARBAMAZEPINE; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLIZING ENZYME; FLAVONOID; FURAFYLLINE; FUROCOUMARIN DERIVATIVE; HALOPERIDOL; KETOCONAZOLE; PHENOBARBITAL; PYRAZOLE; QUINIDINE; RIFAMPICIN; SULFAPHENAZOLE; TICLOPIDINE; TRANYLCYPROMINE; TRYPTAMINE; UNINDEXED DRUG;

CELL FRACTIONATION; CRYOPRESERVATION; CYTOSOLIC FRACTION; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSFORMATION; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HETEROLOGOUS EXPRESSION; HUMAN; IN VITRO STUDY; ISOLATED LIVER; LIVER CELL CULTURE; LIVER MICROSOME; LIVER SLICE; NONHUMAN; PRIMARY CELL CULTURE; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BIOTRANSFORMATION; DRUG EVALUATION, PRECLINICAL; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS;

EID: 84857533589     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012798918426     Document Type: Review

References (104)

1. Pelkonen, O.; Raunio, H. In vitro screening of drug metabolism during drug development: Can we trust the predictions? Expert. Opin. Drug Metab.Toxicol., 2005, 1, 49-59.
2. Singh, S. Preclinical pharmacokinetics: An approach towards safer and efficacious drugs. Curr. Drug. Metab., 2006, 7, 165-182.
3. Krishna, D.R.; Klotz, U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet.1994, 26, 144-160. (Pubitemid 24064238)
4. De Kanter, R.; De Jager, M.H.; Draaisma, A.L.; Jurva, J.U.; Olinga, P.; Meijer, D.K.F.; Groothuis, G.M.M. Drug-metabolizing activity of human and rat liver, lung kidney and intestine slices. Xenobiotica, 2002, 32, 349-362. (Pubitemid 34624631)
5. Xu, C.; Li, C.Y.; Kong, A.T. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res., 2005, 28, 249-268. (Pubitemid 44698742)
6. Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends. Pharmacol. Sci., 2004, 25,193-200. (Pubitemid 38519910)
7. Petzinger, E.; Geyer, J. Drug transporters in pharmacokinetics. Naunyn-Schmiedeberg's Arch. Pharmacol., 2006, 372, 465-475.
8. Adler, S.; Basketter, D.; Creton, S.; Pelkonen, O.; Benthem, J.; Zuang, V.; Andersen, K.E.; Angers-Loustau, A.; Aptula, A.; Bal-Price, A.; Benfenati, E.; Bernauer, U.; Bessems, J.; Bois, F.Y.; Brandon, E.; Bremer, S.; Broschard, T.; Casati, S.; Coecke, S.; Corvi, R.; Cronin, M.; Daston, G.; Dekant, W.; Felter, S.; Grignard, E.; Gundert-Remy, U.; Heinomen, T.; Kimber, I.; Kleinjans, J.; Komulainen, H.; Kreiling, R.; Kreysa, J.; Leiye, S.B.; Loizou, G.; Maxwell, G.; Mazzatorta, P.; Munn, S.; Pfuhler, S.; Phrakonkham, P.; Piersma, A.; Poth, A.; Prieto, P.; Repetto, G.; Rogiers, V.; Schoeters, G.; Schwarz, M.; Serafimova, R.; Tahti, H.; Testai, E.; van Delft, J.; van Loveren, H.; Vinken, M.; Worth, A.; Zaldivar, J. Alternative (non-Animal) methods for cosmetic testing: Current status and future prospect -2010. Arch. Toxicol., 2011, 85, 367-485.
9. Ekins, S.; Ring, B.J.; Grace, J.; McRobie-Belle, D.J.; Wrighton, S.A. Present and future in vitro approaches for drug metabolism. J. Pharmacol. Toxicol., 2000, 44, 313-324. (Pubitemid 32239483)
10. Brandon, E.F.A.; Raap, C.D.; Meijerman, I.; Beijnen, J.H.; Schellens, J.H.M. An update on in vitro test methods in human hepatic drug biotransformation research: Pros and cons. Toxicol. Appl. Pharm., 2003, 189, 233-246. (Pubitemid 36677534)
11. Obach, R.S.; Baxter, J.G.; Liston, T.E.; Silber, M.; Jones, B.C.The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J. Pharmacol. Exp. Ther., 1997, 283, 46-58. (Pubitemid 27438945)
12. Hewitt, N.J.; Buhring, K.U.; Dasenbrock, J.; Haunschild, J.; Ladstetter, B.; Utesch D. Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey and human using cryopreserved hepatocytes, microsomes and collagen gel immobilized hepatocyte cultures. Drug Metab. Dispos., 2001, 29, 1042-1050. (Pubitemid 32605921)
13. Gomez-Lechon, M.J.; Donato, M.T.; Castell, J.V.; Jover, R. Human hepatocytes in primary culture: The choice to investigate drug metabolism in man. Curr. Drug. Metab., 2004, 5, 443-462. (Pubitemid 39276606)
14. Walsky, R.L.; Obach, R.S. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos., 2004, 32, 647-660. (Pubitemid 38668158)
15. Kalvass, J.C.; Tess, D.A.; Giragossian, C.; Linhares, M.C.; Maurer, T.S. Influence of microsomal concentration on apparent intrinsic clearance: Implications for scaling in vitro data. Drug Metab. Dispos., 2001, 29(10), 1337-1342.
16. Bjornsson, T.D.; Callaghan, J.T.; Einolf, H.J.; Fischer, V.; Gan, L.; Grimm, S.; Kao, J.; King, P.S.; Miwa, G.; Ni, L.; Kumar, G.; McLeod, J.; Obach, S.R.; Roberts, S.; Roe, A.; Shah, A.; Snikeris, F.; Sullivan, J.T.; Tweedie, D.; Vega, J.M.; Walsh, J.; Wrighton, S.A. The conduct of in vitro and in vivo drug-drug interaction studies: A pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab.Dispos., 2003, 31(7), 815-832. (Pubitemid 36759050)
17. Easterbrook, J.; Lu, C.; Sakai, Y.; Li, A.P. Effects of organic solvent on the activities of cytochrome P450 isoforms, UDPdependent glucuronyl transferase and phenol sulfotransferase in human hepatocytes. Drug Metab. Dispos., 2001, 29, 141-144. (Pubitemid 32112927)
18. Uchaipichat, V.; Mackenzie, P.I.; Guo, X.; Gardner-Stephen, D.; Aletin, A.; Houston, J.B.; Miners, J.O. Human UDP-glucuronosyl transferases: Isoform selectivity and kinetics of 4-methyl umbelliferone and 1-naphthop glucuronidation, effects of organic solvents and inhibition by diclofenac and probenecid. Drug Metab. Dispos., 2004, 32, 413-423. (Pubitemid 38420275)
19. Li, D.; Han, Y.; Meng, X.; Sun, X.; Yu, Q.; Li, Y.; Wan, L.; Huo, Y.; Guo, C. Effect of regular organic solvents on cytochrome P450-mediated metabolic activities in rat liver microsomes. Drug Metab. Dispos., 2010, 38, 1922-1925.
20. Jones, H.M.; Houston, J.B. Substrate depletion approach for determining in vitro metabolic clearance: Time dependencies in hepatocyte and microsomal incubations. Drug Metab.Dispos., 2004, 32(9), 973-982. (Pubitemid 39096058)
21. Bloomer, J.C.; Baldwin, S.J.; Smith, G.J.; Ayrton, A.D.; Clarke, S.E.; Chenery, R.J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br. J. Clin. Pharmacol., 1994, 38, 557-566. (Pubitemid 24365864)
22. Wang, X.; Lee, W.Y.W.; Or, P.M.Y.; Yeung, J.H.K. Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. Phytomedicine, 2010, 17, 203-211.
23. Walsky, R.L.; Obach, R.S. A comparison of 2-phenyl-2-(1-piperidinyl) propane (PPP), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab. Dispos., 2007, 35, 2053-2059. (Pubitemid 350005195)
24. Pelkonen, O.; Turpeinen, M.; Hakkola, J.; Honkakoski, P.; Hukkanen, J.; Raunio, H. Inhibition and induction of human cytochrome P450 enzymes: Current status. Arch. Toxicol. 2008, 82, 667-715.
25. Zhou, J.; Tracy, T.S.; Remmel, R.P. Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors. Drug Metab. Dispos., 2011, 39, 322-329.
26. Lepine, J.; Bernard, O.; Plante, M.; Tetu, B.; Pelletier, G.; Labrie, F.; Belanger, A.; Guillemette, C. Specificity and regioselectivity of the conjugation of estradiol, estrone and their catecholestrogen and methoxyestrogen metabolites by fuman uridine diphosphoglucuronosyltransferase expressed in endometrium. J. Clin. Endocrinol. Metab., 2004, 89, 5222-5242.
27. Watanabe, Y.; Nakajima, M.; Ohashi, N.; Kume, T.; Yokoi, T. Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab. Dispos., 2003,31, 589-595. (Pubitemid 36444168)
28. Court, M.H. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol., 2005, 400, 104-116. (Pubitemid 43052418)
29. Kasai, N.; Saraki, T.; Shinkyo, R.; Ikushiro, S.; Iyanagi, T.; Ohta, M.; Inouye, K. Metabolism of 26, 26, 26, 27, 27, 27-F6-1 alpha 23S, 25-trihydroxyvitamin D3 by human UDPglucuronosyltransferase 1A3. Drug Metab. Dispos., 2005, 33, 102-107.
30. Uchaipichat, V.; Mackenzie, P.I.; Elliot, D.J.; Miners, J.O. Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine and sulfinpyrazone) "probes" for human UDPglucuronosyltransferases. Drug Metab. Dispos., 2006, 34, 449-456.
31. Qian, M.R.; Zeng, S. Biosynthesis of imipramine glucuronide and characterization of imipramine glucuronidation catalyzed by recombinant UGT1A4. Acta. Pharmacol. Sin., 2006,27, 623-628.
32. Argikar, U.A.; Senekeo-Effenberger, K.; Larson, E.E.; Tukey, R.H.; Remmel, R.P. Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica, 2009, 39, 826-835.
33. Kaku, T.; Ogura, K.; Nishiyama, T.; Ohnuma, T.; Muro, K.; Hiratsuka, A. Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDPglucuronosyltransferase 1A4. Biochem. Pharmacol., 2004, 67, 2093-2102. (Pubitemid 38595490)
34. Krishnaswamy, S.; Hao, Q.; von Moltke, L.L.; Greenblatt, D.J.; Court, M.H. Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6. Drug Metab. Dispos., 2004, 32, 852-869.
35. Su, J.; He, Y.; Wang, C.; Wang, Z. Interspecific difference assay of UDP-glucuronosyltransferase 1A9 activities in liver microsomes by ultra-performance liquid chromatography-tandem mass spectrometry. Chinese J. Nat. Med., 2010, 8, 34-39.
36. Girard, H.; Villeneuve, L.; Court, M.H.; Fortier, L.; Caron, P.; Hao, Q.; von Moltke, L.L.; Greenblatt, D.J.; Guilemette, C. The novel UGT1A9 in tronic 1399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab. Dispos., 2006, 34, 1220-1228.
37. Hanioka, N.; Hayashi, K.; Shimizudani, T.; Nagaoka, K.; Koeda, A.; Naito, S.; Narimatsu, S. Stereoselective glucuronidation of propranolol in human and cynomolgus monkey liver microsomes: Role of human hepatic UDP- glucuronosyltransferase isoforms, UGT1A9, UGT2B4 and UGT2B7. Pharmacology, 2008, 82, 293-303.
38. Pillot, T.; Ouzzine, M.; Fournel-Gigleux, S.; Lafaurie, C.; Radominska, A.; Burchell, B.; Siest, G.; Magdalou, J. Glucuronidation of hyodeoxycholic acid in human liver: Evidence for a selective role of UDP-glucuronosyltransferase 2B4. J. Biol. Chem., 1993, 268, 25636-25636.
39. Uchaipichat, V.; Galetin, A.; Houstin, J.B.; Mackenzie, P.I.; Williams, J.A.; Miners, J.O. Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol and zidovudine glucuronidation by UDP-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol. Pharmacol., 2008, 74, 41152-41162.
40. Stone, A.N.; Mackenzie, P.I.; Galetin, A.; Houstonand, J.B.; Miners, J.O. Isoform selectivity and kinetics of morphine 3-And 3-glucuronidation by human UDP-glucuronosyltransferases: Evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab. Dispos., 2003, 31, 1086-1089. (Pubitemid 37048278)
41. Innocenti, F.; Iyer, L.; Ramirez, J.; Green, M.D.; Ratain, M.J. Epirubicin glucuronidation is catalyzed by human UDPglucuronosyltransferase 2B7. Drug Metab. Dispos., 2001, 29, 686-692. (Pubitemid 32374570)
42. Setlur, S.R.; Chen, C.X.; Hossain, R.R.; Ha, J.S.; van Doren, V.E.; Stenze, B.; Steiner, E.; Oldridge, D.; Kitabayashi, N.; Banerjee, S.; Chen, J.Y.; Schafer, G; Horninger, W.; Lee, C.; Rubin, M.A.; Klocker, H.; Demichelis, F. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol. Biomarkers, 2010, 19, 229.
43. Lafranconi, W.M.; Huxtable, R.J. Hepatic metabolism and pulmonary toxicity of monocrotaline using isolated perfused liver and lung. Biochem. Pharmacol., 1984, 33, 2479-2484. (Pubitemid 14094624)
44. Maier-Salamon, A.; Trauner, G.; Hiltscher, R.; Reznicek, G.; Kopp, B.; Thalhammer, T.; Jager, W. Hepatic metabolism and biliary excretion of valerenic acid in isolated perfused rat livers: Role of Mrp2 (Adcc2). J. Pharm. Sci., 2009, 98, 3839-3849.
45. Ahmed, S.; Vo, N.T.; Thalhammer, T.; Thalhammer, F.; gattringer, K.B.; Jager, W. Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. J. Pharm. Pharmacol., 2008, 60, 55-62.
46. Edwards, R.J.; Price, R.J.; Watts, P.S.; Renwick, A.B.; Tredger, J.M.; Boobis, A.R.; Lake, B.G. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos., 2003, 31, 282-288. (Pubitemid 36249682)
47. Olinga, P.; Elferink, M.G.L.; Draaisma, A.L.; Merema, M.T.; Castell, J.V.; Perez, G.; Groothuis, G.M.M. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur. J. Pharmaceut. Sci., 2008, 33,380-389.
48. De Graaf, I.A.; Olinga, P.; de Jager, M.H.; Merema, M.T.;de Kanter, R.; van de Kerkhof, E.G.; Groothuis, G.M. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat. Protoc., 2010, 5, 1540-1541.
49. Lerche-Langrand, C.; Tourema, M.T., de kanter tain, H.J. Precision-cut liver slices: Characteristics and use for in vitro pharmacotoxicology. Toxicology, 2000, 153, 221-253.
50. Olinga, P.; Hof, I.H.; Merema, M.T.; Smit, M.; De Jager, M.H.; Swart, P.J.; Slooff, M.J.H.; Meijer, D.K.F.; Groothuis, M.M. The applicability of rat and human liver slices to the study of mechanism of hepatic drug uptake. J. Pharmacol. Toxicol., 2001, 45, 55-63. (Pubitemid 32728221)
51. Pan, J.; Xiang, Q.; Renwick, A.B.; Price, R.J.; Ball, S.E.; Kao, J.; Scatina, J.A.; Lake, B.G. Use of a quantitative real-time reverse transcription-polymerase chain reaction method to study the induction of CYP1A, CYP2B and CYP4A forms in precision-cut rat liver slices. Xenobiotica, 2002, 32, 739-747.
52. Janorkar, A.V.; Harris, L.M.; Murphey, B.S.; Sowell, B.L. Use of three dimensional spheroids of hepatocyte-derived reporter cells to study the effects of intracellular fat accumulation and subsequent cytokine exposure. Biotechnol.Bioeng., 2011, 108, 1171-1180.
53. Hewitt, N.J.; Gomez-Lechon, M.J.; Houston, J.B.; Hallifax, D.; Brown, H.S.; Maurel, P.; Kenna, J.G.; Gustavsson, L.; Lohmann, C.; Skonberg, C.; Guillouzo, A.; Tuschl, G.; Li, A.P.; LeCluyse, E.; Groothuis, G.M.; Hengstler J.G. Primary hepatocytes: Current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev., 2007, 39, 159-234.
54. Mudra, D.R.; Parkinson, A.In: Current Protocols in Toxicology, 14, 1-13, published online Aug, 2001. (Accessed July 25, 2011).
55. McGinnity, D.F.; Soars, M.G.; Urbanowicz, R.A.; Riley, R.J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos., 2004, 32, 1247-1253. (Pubitemid 39410908)
56. Wang, K.; Shindoh, H.; Inoue, T.; Horii, I. Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J. Toxicol. Sci., 2002, 27, 229-237. (Pubitemid 34988299)
57. Bi, Y.; Kazolias, D.; Duignan, D.B. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab. Dispos., 2006, 34, 1658-1665. (Pubitemid 44285409)
58. Baccarani, U.; Sanna, A.; Cariani, A.; Sainz-Barriga, M.; Adani, G.L.; Zambito, A.M.; Piccolo, G.; Risaliti, A.; Nanni-Costa, A.; Ridolfi, L.; Scalamoqna, M.; Bresadola, F.; Donini, A. Isolation of human hepatocytes from livers rejected for liver transplantation on national basis: Results of a 2-year experience. Liver Transplant, 2003, 9, 506-512 (Pubitemid 36621721)
59. Guillouzo, A.; Morel, F.; Ratanasavanh, D.; Chesne, C.; Guguen-Guillouzo C. Long-term culture of functional hepatocytes.Toxicol. In vitro, 1990, 4, 415-427. (Pubitemid 20364929)
60. Wang, S.; Nagrath, D.; Chen, P.C.; Bethiaume, F.; Yarmush, M.L. Three-dimensional primary hepatocyte culture in synthetic selfassembling peptide hydrogel. Tissue Eng. Part A, 2008, 14, 227-236.
61. Luttringer, O.; Theil, F.; Lave, T.; Wernli-Kuratli, K.; Guentert, T.W.; De Saizieu, A. Influence of isolation procedure, procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. Biochem. Pharmacol., 2002, 64, 1637-1650. (Pubitemid 35339377)
62. Zaleski, J.; Richburg, J.; Kauffman, F.C. Preservation of the rate and profile of xenobiotic metabolism in rat hepatocytes stored in liquid nitrogen. Biochem. Pharmacol., 1993, 46, 111-116. (Pubitemid 23218588)
63. Ostrowska, A.; Gu, K.; Bode, D.C.; Van Buskirk, R.G. Hypothermic storage of isolated human hepatocytes: A comparison between University of Wisconsin solution and hypothermosol platform. Arch. Toxicol.2009, 83, 493-502.
64. LeCluyse, E.L.; Fix, J.A.; Audus, K.L.; Hochman, J.H. Regeneration and maintenance of bile canalicular networks in collagensandwiched hepatocytes. Toxicol, In vitro, 2000, 14, 117-132. (Pubitemid 30227560)
65. Boess, F.; Kamber, M.; Romer, S.; Gasser, R.; Muller, D.; Albertini, S.; Suter, L. Gene expression in two hepatic cell lines, cultured primary hepatocytes and liver slices compared to the in vitro liver gene expression in rats: Possible implications for toxicogenomics use of in vitro systems. Toxicol. Sci., 2003, 73, 386-402. (Pubitemid 36701742)
66. Strick-Marchand, H.; Weiss, M.C. Inducible differentiation and morphogenesis of bipotential liver cell lines from wild-type mouse embryos.Hepatology, 2002, 36, 794-804.
67. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A.; Karlsson, J. expreesion of thirty-six drug rransporter genes in human intestine, liver, kidney and organotypic cell lines. Drug Metab. Dispos., 2007, 35, 1333-1340. (Pubitemid 47121774)
68. Khetani, S.R.; Bhatia, S. Microscale culture of human liver cells for drug development.Nat. Biotechnol., 2008, 26, 120-126.
69. Xu, L.; Hui, A.Y.; Albanis, E.; Arthur, M.J.; O'Byrne, S.M.; Blaner, W.S.; Mukheriee, P.; Friedman, S.L.; Eng, F.J. Human hepatic stellate cell lines, LX-1 and LX-2: New tools for analysis of hepatic fibrosis. Gut, 2005, 54, 142-151. (Pubitemid 40007234)
70. Khalil, M.; Shariat-Panahi, A.; Tootle, R.; Ryder, T.; McCloskey, P.; Roberts, E.; Hodgson, H.; Selden, C. Human hepatocyte cell lines proliferating as cohesive spheroid colonies in alginate markedly upregulate both synthetic and detoxificatory liver function. J. Hepatol., 2001, 34, 68-77. (Pubitemid 32102554)
71. Mersch-Sundermann, V.; Knasmuller, S.; Wu, X.; Darroudi, F.; Kassie, F. Use of human-derived liver cell line for the detection of cytoprotective, antigenotoxic and cogenotoxic agents. Toxicology, 2004, 198, 329-340. (Pubitemid 38609044)
72. Gripon, P.; Rumin, S.; Urban, S.; Le Seyec, J.; Glaise, D.; Cannie, I.; Guyomard, C.; Lucas, J.; Trepo, C.; Guguen-Guillouzo, C. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. USA., 2002, 99, 15655-15660. (Pubitemid 35403987)
73. Kanebratt, K.P.; Andersson, T.B. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies.Drug Metab. Dispos., 2008, 36(7), 1444-1452 (Pubitemid 351929328)
74. Lubberstedt, M.; Muller-Vieira, U.; mayer, M.; Biemel, K.M.; Knospel, F.; Knobeloch, D.; Nussler, A.K.; Gerlach, J.C.; Zeilinger, K. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J. Pharmacol. Toxicol. Methods, 2011, 63, 59-68.
75. Darnell, M.; Schreiter, T.; Zeilinger, K.; Urbaniak, T.; Soderdahl, T.; Rossberg, I.; Dillner, B.; Berg, A.L.; Gerlach, J.C.; Andersson, T.B. Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimentional bioreactor. Drug Metab. Dispos., 2011, 7, 1131-1138.
76. Hakura, A.; Suzuki, S.; Sawada, S.; Motooka, S.; Satoh, T. An improvement of the Ames test using a modified human liver S9 preparation. J Pharmacol. Toxicol., 2001, 46, 169-172. (Pubitemid 35245308)
77. Slaughter, D.; Takenaga, N.; Lu, P.; Assang, C.; Walsh, D.J.; Arison, B.H.; Cui, D.; Halpin, R.A.; Geer, L.A.; Vyas, K.P.; Baillie, T.A. Metabolism of rofecoxib in vitro using human liver subcellular fractions. Drug Metab. Dispos., 2003, 31, 1398-1408. (Pubitemid 37310330)
78. Chalbot, S.; Morfin, R. Human liver S9 fractions: Metabolism of dehydroepiandrosterone, epiandrosterone and related 7-hydroxylated derivatives. Drug Metab. Dispos., 2005, 33, 563-569. (Pubitemid 40393200)
79. Hakura, A.; Suzuki, S.; Sawada, S.; Sugihara, T.; Hori, Y.; Uchida, K.; Kerns, W.D.; Sagami, F.; Motooka, S.; Satoh, T. Use of human S9 in the Ames test: Assay of three procarcinogens using human S9 derived from multiple donors. Regul. Toxicol. Pharm., 2003, 37, 20-27. (Pubitemid 36349334)
80. Hakura, A.; Suzuki, S.; Satoh, T. Advantage of the use of human liver S9 in the Ames test. Mutat. Res-Gen. Tox. En., 1999, 438, 29-36. (Pubitemid 29015748)
81. Maser, E.; Stinner, B.; Atalla, A. Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. Cancer Lett., 2000, 148 135-144. (Pubitemid 30047100)
82. Walsh, J.S.; Reese, M.J.; Thurmond, L.M. The metabolic activation of abacavir by human liver cytosol and expressed human alcohol and dehydrogenase isozymes. Chem. Biol. Interact., 2002, 142, 135-154. (Pubitemid 35238046)
83. Li, Y.; Tyan, Y.; Lee, Y.; Tsao, T.; Chuang, J.; Kuo, H.; Hsia, T.; Yang, J.; Chung, J. N-Acetyltransferase is involved in baicaleininduced N-Acetylation of 2-Aminofluorene and DNA-2-Aminofluorene adduct formation in human leukemia HL-60 cells. In vivo, 2005, 19, 399-405.
84. Buenz, E.J. A high-throughput cell-based toxicity analysis of drug metabolites using flow cytometry. Cell Biol. Toxicol., 2007, 23, 361-365. (Pubitemid 46919122)
85. Bu, H.Z. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: Structure-kinetics relationship assessment. Curr. Drug Metab., 2006, 7, 231-249.
86. Asha, S.; Vidyavathi, M. Role of human liver microsomes in in vivo metabolism of drugs -A review.Appl. Biochem. Biotechnol., 2010, 160, 1699-1722.
87. Newton, D.J.; Wang, R.W.; Evans, D.C. Determination of phase I metabolic enzyme activities in liver microsomes of Mrp2 deficient TR and EHBR rats. Life Sci., 2005, 77, 1106-1115. (Pubitemid 40835889)
88. Pearce, R.E.; McIntyre, C.J.; Madan, A.; Sanzgiri, U.; Draper, A.J.; Bullock, P.L.; Cook, D.C.; Burton, L.A.; Latham, J.; Nevins, C.; Parkinson, A. Effects of freezing, thawing and storing human liver microsomes on cytochrome P450 activity. Arch. Biochem. Biophys., 1996, 331,145-169. (Pubitemid 26256063)
89. Yamazaki, H.; Inoue, K.; Turvy, C.G.; Guengerich, F.P.; Shimada, T. Effects of freezing, thawing and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos., 1997, 25, 168-174. (Pubitemid 27086117)
90. Chen, M.; Howe, D.; Leduc, B.; Kerr, S.; Williams, D.A. Identification and characterization of two chloramphenicol glucuronides from the in vitro glucuronidation of chloramphenicol in human liver microsomes. Xenobiotica, 2007, 37, 954-971. (Pubitemid 47482946)
91. Venkatakrishnan, K.; von Moltke, L.L.; Greenblatt, D.J. Application of the relative activity factor approach in scaling from heterologously expressed cytochrome P450 to human liver microsomes: Studies on amitriptyline as a model substrate. JPET., 2001, 297, 326-337. (Pubitemid 32242593)
92. Lu, A.Y.H.; Wang, R.W.; Lin, J.H. Cytochrome P450 in vitro reaction phenotyping: A re-evaluation of approaches used for P450 isoform identification. Drug Metab. Dispos. 2003, 31, 345-350. (Pubitemid 36378510)
93. Xenotech Product Information.http://www.xenotechllc.com (Accessed July 20, 2011)
94. Donato, M.T.; Lahoz, A.; Castell, J.V.; Gomez-Lechon, M.J. Cell lines: A tool for in vitro drug metabolism studies. Curr. Drug Metab., 2008, 9, 1-11. (Pubitemid 351201665)
95. Crespi, C.L.; Langenbach, R.; Penman, B.W. Human cell lines, derived from AHH-1 TK+/-human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicology, 1993, 82, 89-104.
96. Snawder, J.E.; Roc, A.L.; Benson, R.W.; Casciano, D.; Roberts, D.W. Cytochrome P450-dependent metabolism of acetaminophen in four human transgenic lymphoblastoid cell lines. Pharmacogenetics, 1994, 4, 43-46. (Pubitemid 24106123)
97. Sawada, M.; Kamataki, T. Genetically engineered cells stably expressing cytochrome P450 and their application to mutagen assays. Mutation Res., 1998, 411, 19-43. (Pubitemid 28321479)
98. Guengerich, F.P.; Parikh, A.; Johnson, E.F.; Richardson, T.H.; von Wachenfeldt, C.; Cosme, J.; Jung, F.; Strassburg, C.P.; Manns, M.P.; Tukey, R.H.; Pritchard, M.; Fournel-Gigleux, S.; Burchell, B. Heterologous expression of human drug-metabolizing enzymes. Drug Metab.Dispos.,1997, 25, 1234-1241. (Pubitemid 27490666)
99. Miller, V.P.; Stocker, P.J.; Steimel-Crespi, D.T.; Steinberg, S.L.; McNamara, J.; Code E.L.; Parikh, S.; Shimada, N.; Crespi, C.L. Characterization of cDNA-expressed rat P450 enzymes in microsomes prepared from baculovirus infected insect cells (Supersomes ®). Gentest Corporation 2011; http://www.bdj.co.jp/gentest/articles/hkdqj2000001ewocatt/Poster6-9-Rat-CYPs. pdf (Accessed July 27, 2011).
100. Lavigne, J.A.; Nakatsu, K.; Marks, G.S. Identification of human hepatic cytochrome P450 sources of N-Alkylprotoporphyrin IX after interaction with porphyrinogenic xenobiotics, implications for detection of xenobiotic-induced porphyria in humans. Drug Metab. Dispos., 2002, 30, 788-794. (Pubitemid 34671091)
101. Invirogen Life Technology 2004. Drug metabolizing enzymes -Technical Resource Guide, 2nd Ed., http://tools.invitrogen.com/downloads/O-12758DMEGuide- Intro.pdf (Accessed July 23,2011).
102. Kurkela, M.; Garci'a-Horsman, J.A.; Luukkanen, L.; Morsky, S.; Taskinen, J.; Baumann M.; Kostiainen, R.; Hirvonen, J.; Finel, M. Expression and characterization of recombinant human UDPglucuronosyltransferases (UGTs). J. Biol. Chem., 2003, 278, 3536-3544.
103. Wang, S.; Rijk, J.C.W.; Riethoff-Poortman, J.H.; van Kujik, S.; Peijinenburg, A.A.C.M.; Bovee, T.F.H. Bovine liver slices combined with an androgen transcriptional activation assay: An in vitro model to study the metabolism and bioactivity of steroids. Anal Bioanal. Chem., 2010, 397, 631-641.
104. Schwarz, D.; Kisselev, P.; Honeck, H.; Cascorbi, I.; Schunck, W.H.; Roots, I. Co-expression of human cytochrome P4501A1 (CYP1A1) variants and human NADPH-cytochrome P450 reductase in the baculovirus/insect cell system. Xenobiotica, 2001, 31, 345-356. (Pubitemid 32679312)